STARTVerso 4 Phase iii trial of faldaprevir once-daily plus peg interferon α-2a and ribavirin (PR) in patients with HiV and HCV genotype-1 co-infection

Provided by NATAP

Reported by Jules Levin
14th European AiDS Conference, October 16-19, 2013, Brussels, Belgium

JK Rockstroh1, M Nelson2, V Soriano3, K Arastéh4, J Guardiola5, S Bhagani6, J Mallolas7, C Tural8, M Puoti9, P ingiliz10, M Battegay11, MK Jain12, M Nunez13, K Marks14, J Kort15, JO Stern15, R Vinisko15, M Manero16, D Dieterich17

1University of Bonn, Bonn, Germany; 2Chelsea and Westminster Hospital, London, UK; 3Hospital Carlos iii, Madrid, Spain; 4EPiMED, Vivantes Auguste-Viktoria Hospital, Berlin, Germany; 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Royal Free Hospital, London, UK; 7Hospital Clínic, Barcelona, Spain; 8Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 9AO Ospedale Niguarda Ca Granda, Milan, italy; 10Medizinisches infektiologiezentrum Berlin (MiB), Berlin, Germany; 11Division of infectious Diseases and Hospital Epidemiology, Basel, Switzerland; 12UT Southwestern Medical Center, Dallas, TX, USA; 13Wake Forest University, Winston-Salem, NC, USA; 14Weill Cornell Medical College, NY, USA; 15Boehringer ingelheim Pharmaceuticals inc. Ridgefield, USA; 16Boehringer ingelheim Espana S.A., Barcelona, Spain; 17Mount Sinai School of Medicine, NY, USA

Continue here to view posters …..